한글목차

전 세계 뎅기열 백신 시장 규모는 2019년 260만 달러로 2024년까지 174.00% 이상의 CAGR로 성장할 것으로 예상됩니다.

뎅기열 발병률 증가

뎅기열 발병률의 증가는 과거 기간 동안 뎅기열 백신 시장의 성장을 뒷받침했습니다. 뎅기열 환자가 급증함에 따라 정부, 의료 기관 및 개인은 효과적인 예방 전략을 우선순위에 두고 있습니다. 백신 접종은 특히 모기 매개 질병에 취약한 지역에서 뎅기열 발생을 관리하는 데 있어 매우 중요한 솔루션으로 부상하고 있습니다. 이러한 전염병은 입원, 의료 치료, 노동 생산성 저하로 인해 막대한 의료 비용과 경제적 혼란을 초래하는 경우가 많습니다. 따라서 이해관계자들은 백신 접종이 이 질병의 전반적인 영향을 줄일 수 있는 비용 효율적인 접근법이라고 인식하고 있습니다. 예를 들어, 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)에 따르면, 2024년 5월, 아메리카 지역의 뎅기열 환자 수가 700만 명을 넘어섰으며, 2023년에 기록된 460만 명에서 크게 증가했습니다. 따라서 뎅기열 발병률의 증가는 뎅기열 백신 시장의 성장을 촉진했습니다.

세계의 뎅기열 백신 시장에 대해 조사 분석했으며, 시장의 특징과 주요 시장 동향, 시장 규모와 성장 전망, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 주요 요약

• 뎅기열 백신 - 시장 매력과 거시경제 상황

제2장 목차

제3장 표목차

제4장 그림목차

제5장 보고서 구성

제6장 시장 특징

• 일반적인 시장 정의
• 요약
• 뎅기열 백신 시장 정의와 세분화
• 시장 세분화 : 유형별
  • 생 백신
  • 불활화 백신
  • 아단위 백신
  • 핵산 백신
• 시장 세분화 : 투여 경로별
  • 경구
  • 비경구
  • 기타 치료
• 시장 세분화 : 최종사용자별
  • 병원
  • 진료소
  • 정부기관
  • 비정부 조직
  • 기타 최종사용자

제7장 주요 시장 동향

• 뎅기열 감염 조기 발견을 위한 진단키트 발전
• 전 세계 뎅기열 발병률 증가에 대응하는 새로운 뎅기열 치료 솔루션에 투자
• 뎅기열 백신 시장에서 혁신을 촉진하는 전략적 파트너십 체결

제8장 뎅기열 백신 시장 - 거시경제 시나리오

• 뎅기열 백신 시장에 대한 COVID-19의 영향
• 뎅기열 백신 시장에 대한 우크라이나 전쟁의 영향
• 뎅기열 백신 시장에 대한 고인플레이션의 영향

제9장 세계의 시장 규모와 성장

• 시장 규모
• 시장 성장 실적(2019-2024년)
  • 시장 성장 촉진요인(2019-2024년)
  • 시장 성장 억제요인(2019-2024년)
• 시장 성장 예측(2024-2029년·2034년)
  • 시장 성장 촉진요인(2024-2029년)
  • 시장 성장 억제요인(2024-2029년)

제10장 세계의 뎅기열 백신 시장 세분화

• 세계의 뎅기열 백신 시장 : 유형별, 실적과 예측(2019-2024년·2029년·2034년)
• 세계의 뎅기열 백신 시장 : 투여 경로별, 실적과 예측(2019-2024년·2029년·2034년)
• 세계의 뎅기열 백신 시장 : 최종사용자별, 실적과 예측(2019-2024년·2029년·2034년)

제11장 뎅기열 백신 시장, 지역과 국가 분석

• 세계의 뎅기열 백신 시장 : 지역별, 실적과 예측(2019-2024년·2029년·2034년)
• 세계의 뎅기열 백신 시장 : 국가별, 실적과 예측(2019-2024년·2029년·2034년)

제12장 아시아태평양 시장

제13장 서유럽 시장

제14장 동유럽 시장

제15장 북미 시장

제16장 남미 시장

제17장 중동 시장

제18장 아프리카 시장

제19장 경쟁 구도와 기업 개요

• 기업 개요
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Panacea Biotec Ltd

제20장 기타 주요 기업과 혁신적 기업

• Codagenix Inc
• Serum Institute of India
• Inovio Pharmaceuticals Inc
• Novavax, Inc
• Medigen Vaccine Biologics Corporation
• The International Vaccine Institute(ivi.int)
• Bharat Biotech International Limited
• Sinovac Biotech Ltd
• SABIN Vaccine Institute Inc
• VabioTech
• BioNet-Asia Co. Ltd
• Hilleman Laboratories Pvt. Ltd
• Biological E. Limited
• K.M. Biologics
• Emergex

제21장 경쟁 벤치마킹

제22장 경쟁 대시보드

제23장 기회와 전략

• 세계의 뎅기열 백신 시장 - 가장 새로운 기회를 제공하는 국가(2029년)
• 세계의 뎅기열 백신 시장 - 가장 새로운 기회를 제공하는 부문(2029년)
• 세계의 뎅기열 백신 시장 - 성장 전략(2029년)
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제24장 뎅기열 백신 시장 : 결론과 제안

• 결론
• 제안
  • 제품
  • 유통
  • 가격
  • 프로모션
  • 사람들

제25장 부록

영문목차

A dengue vaccine is a biological preparation designed to protect individuals against dengue fever, a viral infection caused by the dengue virus (DENV). This virus is transmitted primarily through the bite of infected Aedes mosquitoes, especially Aedes aegypti. Dengue fever causes a range of symptoms, from mild flu-like illness to severe complications such as dengue hemorrhagic fever and dengue shock syndrome, which can be life-threatening.

The dengue vaccine market consists of sales by entities (organizations, sole traders and partnerships) of dengue vaccine that focuses on providing solutions to mitigate the severe health risks associated with the disease, which can range from flu-like symptoms to life-threatening complications like dengue hemorrhagic fever and dengue shock syndrome.

The global dengue vaccine market was valued at $2.60 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 174.00%.

Rising Dengue Incidence

The rising dengue incidence supported the growth of the dengue vaccine market during the historic period. With the surge in dengue cases, governments, healthcare organizations and individuals are prioritizing effective prevention strategies. Vaccination emerges as a pivotal solution in managing dengue outbreaks, particularly in regions prone to mosquito-borne diseases. These outbreaks often result in substantial healthcare expenses and economic disruptions, driven by hospitalizations, medical care and decreased workforce productivity. Consequently, stakeholders recognize vaccination as a cost-efficient approach to mitigating the overall impact of the disease. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, a significant increase from the 4.6 million cases recorded in 2023. Therefore, the rising dengue incidence drove the growth of the dengue vaccine market.

Investment In Novel Dengue Treatment Solutions To Address Rising Global Incidence

Major companies operating in the dengue vaccine market are focusing on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access. Strategic investments drive the growth of the dengue vaccine market by boosting funding for research and development, allowing manufacturers to develop more efficient and advanced vaccines. For instance, in October 2023, Codagenix Inc., a US-based clinical-stage biotechnology company focused on developing vaccines received an award of $5.88 million from U.S. Department of Defense (DoD) to further develop its dengue vaccine candidate, CodaVax-DENV. The funding will support the initiation of a first-in-human Phase 1 trial, which will evaluate the vaccine's safety and immunogenicity. This initiative aligns with a broader strategy to combat dengue fever, a significant health threat, particularly for military personnel deployed in endemic regions.

The global dengue vaccine market is highly concentrated, with few players operating in the market. The top ten competitors in the market made up to 100.0% of the total market in 2023.

Dengue Vaccine Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global dengue vaccine market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for dengue vaccine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The dengue vaccine market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider dengue vaccine market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by route of administration and by end user.
• Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the dengue vaccine market.
• Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by route of administration and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for dengue vaccine market providers in terms of product/service offerings geographic expansion, marketing strategies and target groups next five years.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Live Attenuated Vaccine; Inactivated Vaccine; Subunit Vaccine; Nucleic Acid-Based Vaccine
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By End User: Hospitals; Clinics; Government Institutes; Non-Governmental Organizations; Other End-Users
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Sanofi SA; GlaxoSmithKline plc; Merck & Co. Inc.; Panacea Biotec Ltd.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; dengue vaccine indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Dengue Vaccine - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Dengue Vaccine Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Live Attenuated Vaccine
  • 6.4.2 Inactivated Vaccine
  • 6.4.3 Subunit Vaccine
  • 6.4.4 Nucleic Acid-Based Vaccine
• 6.5 Market Segmentation By Route of Administration
  • 6.5.1 Oral
  • 6.5.2 Parenteral
  • 6.5.3 Other Treatment
• 6.6 Market Segmentation By End User
  • 6.6.1 Hospital
  • 6.6.2 Clinic
  • 6.6.3 Government Institutes
  • 6.6.4 Non-Governmental Organizations
  • 6.6.5 Other End-Users

7 Major Market Trends

• 7.1 Advancements In Diagnostic Kits For Early Detection Of Dengue Infections
• 7.2 Investment In Novel Dengue Treatment Solutions To Address Rising Global Incidence
• 7.3 Strategic Partnerships Driving Innovation In The Dengue Vaccine Market

8 Dengue Vaccine Market - Macro Economic Scenario

• 8.1 COVID-19 Impact On The Dengue Vaccine Market
• 8.2 Impact Of The War In Ukraine On The Dengue Vaccine Market
• 8.3 Impact Of High Inflation On The Dengue Vaccine Market

9 Global Market Size and Growth

• 9.1 Market Size
• 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 9.2.1 Market Drivers 2019 - 2024
  • 9.2.2 Market Restraints 2019 - 2024
• 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 9.3.1 Market Drivers 2024 - 2029
  • 9.3.2 Market Restraints 2024 - 2029

10 Global Dengue Vaccine Market Segmentation

• 10.1 Global Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.3 Global Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Dengue Vaccine Market, Regional and Country Analysis

• 11.1 Global Dengue Vaccine Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.2 Global Dengue Vaccine Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate Tax Structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Asia-Pacific Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Asia-Pacific Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Asia-Pacific Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Asia-Pacific Dengue Vaccine Market: Country Analysis
• 12.7 China Market
• 12.8 Market Overview
  • 12.8.1 Country Information
  • 12.8.2 Market Information
  • 12.8.3 Background Information
  • 12.8.4 Government Initiatives
  • 12.8.5 Regulations
  • 12.8.6 Regulatory Bodies
  • 12.8.7 Major Associations
  • 12.8.8 Taxes Levied
  • 12.8.9 Corporate Tax Structure
  • 12.8.10 Major Companies
• 12.9 China Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 China Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 China Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.12 India Market
• 12.13 India Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 India Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 India Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.16 Japan Market
• 12.17 Japan Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 Japan Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Japan Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.20 Australia Market
• 12.21 Australia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Australia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Australia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.24 Indonesia Market
• 12.25 Indonesia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Indonesia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.27 Indonesia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.28 South Korea Market
• 12.29 South Korea Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.30 South Korea Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.31 South Korea Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate tax structure
  • 13.2.10 Investments
  • 13.2.11 Major Companies
• 13.3 Western Europe Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Western Europe Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Western Europe Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Western Europe Dengue Vaccine Market: Country Analysis
• 13.7 UK Market
• 13.8 UK Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 UK Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 UK Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.11 Germany Market
• 13.12 Germany Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.13 Germany Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.14 Germany Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.15 France Market
• 13.16 France Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.17 France Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.18 France Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.19 Italy Market
• 13.20 Italy Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.21 Italy Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.22 Italy Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.23 Spain Market
• 13.24 Spain Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.25 Spain Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.26 Spain Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Regulations
  • 14.2.5 Regulatory Bodies
  • 14.2.6 Major Associations
  • 14.2.7 Taxes Levied
  • 14.2.8 Corporate Tax Structure
  • 14.2.9 Major companies
• 14.3 Eastern Europe Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 Eastern Europe Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 Eastern Europe Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 Eastern Europe Dengue Vaccine Market: Country Analysis
• 14.7 Russia Market
• 14.8 Russia Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.9 Russia Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.10 Russia Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 North America Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 North America Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 North America Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 North America Dengue Vaccine Market: Country Analysis
• 15.7 USA Market
• 15.8 Summary
• 15.9 Market Overview
  • 15.9.1 Country Information
  • 15.9.2 Market Information
  • 15.9.3 Background Information
  • 15.9.4 Government Initiatives
  • 15.9.5 Regulations
  • 15.9.6 Regulatory Bodies
  • 15.9.7 Major Associations
  • 15.9.8 Taxes Levied
  • 15.9.9 Corporate Tax Structure
  • 15.9.10 Investments
  • 15.9.11 Major Companies
• 15.10 USA Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.11 USA Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.12 USA Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.13 Canada Market
• 15.14 Canada Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.15 Canada Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.16 Canada Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 South America Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 South America Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 South America Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.6 South America Dengue Vaccine Market: Country Analysis
• 16.7 Brazil Market
• 16.8 Brazil Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.9 Brazil Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.10 Brazil Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Middle East Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Middle East Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Middle East Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

• 18.1 Market Overview
  • 18.1.1 Region Information
  • 18.1.2 Market Information
  • 18.1.3 Background Information
  • 18.1.4 Government Initiatives
  • 18.1.5 Regulations
  • 18.1.6 Regulatory Bodies
  • 18.1.7 Major Associations
  • 18.1.8 Taxes Levied
  • 18.1.9 Corporate Tax Structure
  • 18.1.10 Major Companies
• 18.2 Africa Dengue Vaccine Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.3 Africa Dengue Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 18.4 Africa Dengue Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape and Company Profiles

• 19.1 Company Profiles
• 19.2 Takeda Pharmaceutical Company Limited
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
  • 19.2.3 Business Strategy
  • 19.2.4 Financial Overview
• 19.3 Sanofi S.A.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
  • 19.3.3 Financial Overview
• 19.4 GlaxoSmithKline plc
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
  • 19.4.3 Business Strategy
  • 19.4.4 Financial Overview
• 19.5 Merck & Co., Inc.
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
  • 19.5.3 Business Strategy
  • 19.5.4 Financial Overview
• 19.6 Panacea Biotec Ltd
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
  • 19.6.3 Business Strategy
  • 19.6.4 Financial Overview

20 Other Major And Innovative Companies

• 20.1 Codagenix Inc
  • 20.1.1 Company Overview
  • 20.1.2 Products and Services
• 20.2 Serum Institute of India
  • 20.2.1 Company Overview
  • 20.2.2 Products And Services
• 20.3 Inovio Pharmaceuticals Inc
  • 20.3.1 Company Overview
  • 20.3.2 Products and Services
• 20.4 Novavax, Inc
  • 20.4.1 Company Overview
  • 20.4.2 Products And Services
• 20.5 Medigen Vaccine Biologics Corporation
  • 20.5.1 Company Overview
  • 20.5.2 Products and Services
• 20.6 The International Vaccine Institute (ivi.int)
  • 20.6.1 Company Overview
  • 20.6.2 Products and Services
• 20.7 Bharat Biotech International Limited
  • 20.7.1 Company Overview
  • 20.7.2 Products and Services
• 20.8 Sinovac Biotech Ltd
  • 20.8.1 Company Overview
  • 20.8.2 Products and Services
• 20.9 SABIN Vaccine Institute Inc
  • 20.9.1 Company Overview
  • 20.9.2 Products and Services
• 20.10 VabioTech
  • 20.10.1 Company Overview
  • 20.10.2 Products and Services
• 20.11 BioNet-Asia Co. Ltd
  • 20.11.1 Company Overview
  • 20.11.2 Products and Services
• 20.12 Hilleman Laboratories Pvt. Ltd
  • 20.12.1 Company Overview
  • 20.12.2 Products and Services
• 20.13 Biological E. Limited
  • 20.13.1 Company Overview
  • 20.13.2 Products and Services
• 20.14 K.M. Biologics
  • 20.14.1 Company Overview
  • 20.14.2 Products and Services
• 20.15 Emergex
  • 20.15.1 Company Overview
  • 20.15.2 Products and Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Opportunities And Strategies

• 23.1 Global Dengue Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 23.2 Global Dengue Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 23.3 Global Dengue Vaccine Market In 2029 - Growth Strategies
  • 23.3.1 Market Trend Based Strategies
  • 23.3.2 Competitor Strategies

24 Dengue Vaccine Market, Conclusions And Recommendations

• 24.1 Conclusions
• 24.2 Recommendations
  • 24.2.1 Product
  • 24.2.2 Place
  • 24.2.3 Price
  • 24.2.4 Promotion
  • 24.2.5 People

25 Appendix

• 25.1 Geographies Covered
• 25.2 Market Data Sources
• 25.3 Research Methodology
• 25.4 Currencies
• 25.5 The Business Research Company
• 25.6 Copyright and Disclaimer